Laura A. Goguen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura A. Goguen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Charles M. Norris
Division of Otolaryngology, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA
6 shared publicationsDonald J. Annino
Division of Otolaryngology, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA
6 shared publicationsRobert I. Haddad
Department of Medical Oncology, Dana–Farber Cancer Institute; Department of Medicine, Brigham and Women's Hospital; and Department of Medicine, Harvard Medical School, Boston, MA, USA
5 shared publicationsRoy B. Tishler
Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA, USA
5 shared publicationsClaudia I. Chapuy
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
4 shared publications- Robert I. Haddad
Dana-Farber Cancer Institute, Boston, MA, USA
3 shared publications
Latest Publications
- 18 June 2013
- Published by Wiley in The Laryngoscope
- Vol. 123 (12) , 3066-3073
Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment
Objectives/Hypothesis: To assess clinical success and safety of endoscopic pharyngoesophageal dilation after chemoradiation or radiation for head and neck cancer and to identify variables associated with dilation failure.Study Design: Case series with chart review.Methods: Between 2000 and 2008, a total of 111 patients treated with chemoradiation or radiation for head and neck cancer with subsequent pharyngoesophageal stenosis requiring endoscopic dilation were identified. Patients were evaluated for endoscopic dilation technique, severity of stenosis, technical and clinical success, and intra‐ and postoperative complications. The Diet/GT score (range, 1–5) was utilized to measure swallow success. Variables associated with dilation failure were analyzed by univariate and multivariate logistic regression.Results: There were 271 dilations analyzed, with 42 combined antegrade retrograde dilations, 208 dilations over a guidewire, and 21 dilations without guidewire. Intraoperative patency and successful dilation of the stenotic segment was achieved in 95% of patients. A Diet/GT score of 5 (gastrostomy tube removed and soft/regular diet) was attained in 84 of 111 (76%) patients. Safety analysis showed complications occurred in 9% of all dilations. Perforations were noted in 4% of all procedures, with only two esophageal perforations requiring significant intervention. Multiple dilations were associated with an increased risk for perforations. Further logistic regression analyses revealed that the number of dilations was indicating a poor outcome and low Diet/GT score.Conclusions: Pharyngoesophageal stenosis, occurring after chemoradiation and radiation treatment, can be successfully and safely treated with endoscopic dilation techniques. Patients with restenosis, requiring multiple dilations, have a higher risk of persistent dysphagia.Level of Evidence: 4 Laryngoscope, 123:3066–3073, 2013
- 18 June 2013
- Published by Wiley in The Laryngoscope
- Vol. 123 (12) , 3066-3073
Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment
Objectives/Hypothesis: To assess clinical success and safety of endoscopic pharyngoesophageal dilation after chemoradiation or radiation for head and neck cancer and to identify variables associated with dilation failure.Study Design: Case series with chart review.Methods: Between 2000 and 2008, a total of 111 patients treated with chemoradiation or radiation for head and neck cancer with subsequent pharyngoesophageal stenosis requiring endoscopic dilation were identified. Patients were evaluated for endoscopic dilation technique, severity of stenosis, technical and clinical success, and intra‐ and postoperative complications. The Diet/GT score (range, 1–5) was utilized to measure swallow success. Variables associated with dilation failure were analyzed by univariate and multivariate logistic regression.Results: There were 271 dilations analyzed, with 42 combined antegrade retrograde dilations, 208 dilations over a guidewire, and 21 dilations without guidewire. Intraoperative patency and successful dilation of the stenotic segment was achieved in 95% of patients. A Diet/GT score of 5 (gastrostomy tube removed and soft/regular diet) was attained in 84 of 111 (76%) patients. Safety analysis showed complications occurred in 9% of all dilations. Perforations were noted in 4% of all procedures, with only two esophageal perforations requiring significant intervention. Multiple dilations were associated with an increased risk for perforations. Further logistic regression analyses revealed that the number of dilations was indicating a poor outcome and low Diet/GT score.Conclusions: Pharyngoesophageal stenosis, occurring after chemoradiation and radiation treatment, can be successfully and safely treated with endoscopic dilation techniques. Patients with restenosis, requiring multiple dilations, have a higher risk of persistent dysphagia.Level of Evidence: 4 Laryngoscope, 123:3066–3073, 2013
- 1 July 2012
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 33 (4) , 700-711
Acupuncture for dysphagia after chemoradiation in head and neck cancer: Rationale and design of a randomized, sham-controlled trial
- 1 July 2012
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 33 (4) , 700-711
Acupuncture for dysphagia after chemoradiation in head and neck cancer: Rationale and design of a randomized, sham-controlled trial
- 18 March 2011
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 145 (3) , 428-434
Swallowing Function following Postchemoradiotherapy Neck Dissection
Objective: This study assesses swallowing function following chemoradiotherapy and neck dissection in head and neck cancer patients and investigates clinical, treatment, and neck dissection factors associated with dysphagia.Study Design: Case series with chart review.Setting: Tertiary care center.Subjects and Methods: Eighty‐eight patients undergoing neck dissection after chemoradiotherapy for advanced head and neck cancer were reviewed. Dysphagia outcome measures included weight loss, diet, gastrostomy tube (GT) dependency, and video swallow findings of aspiration or stenosis. In addition, the researchers created a Diet/GT Scale, with scores ranging from 1 to 5. Univariate and multivariate analysis of clinical, treatment, or neck dissection factors potentially associated with dysphagia outcome measures was undertaken.Results: Peak mean weight loss was 17% at 6 months after chemoradiotherapy. At 12 months, a soft/regular diet was taken by 78 of 88 patients (89%), and only 1 of 88 patients (1%) was nil per os. Gastrostomy tube dependence at 6, 12, and 24 months was 53%, 25%, and 10%, respectively. The Diet/GT score was 5 (gastrostomy tube removed and soft/regular diet) for 47% at 6 months, 74% at 12 months, and 89% at 24 months. Multivariate analyses revealed that higher tumor stage was associated with a lower Diet/GT score at 12 months (P =. 02) and gastrostomy dependence at 12 months (P =. 01) and 24 months (P =. 04).Conclusion: Despite the addition of neck dissection to chemoradiotherapy, nearly all patients took a soft or regular diet and reached a Diet/GT score of 5, and only 1% remained nil per os. A higher tumor stage is associated with a lower Diet/GT score and gastrostomy tube dependency beyond 12 months.
- 18 March 2011
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 145 (3) , 428-434
Swallowing Function following Postchemoradiotherapy Neck Dissection
Objective: This study assesses swallowing function following chemoradiotherapy and neck dissection in head and neck cancer patients and investigates clinical, treatment, and neck dissection factors associated with dysphagia.Study Design: Case series with chart review.Setting: Tertiary care center.Subjects and Methods: Eighty‐eight patients undergoing neck dissection after chemoradiotherapy for advanced head and neck cancer were reviewed. Dysphagia outcome measures included weight loss, diet, gastrostomy tube (GT) dependency, and video swallow findings of aspiration or stenosis. In addition, the researchers created a Diet/GT Scale, with scores ranging from 1 to 5. Univariate and multivariate analysis of clinical, treatment, or neck dissection factors potentially associated with dysphagia outcome measures was undertaken.Results: Peak mean weight loss was 17% at 6 months after chemoradiotherapy. At 12 months, a soft/regular diet was taken by 78 of 88 patients (89%), and only 1 of 88 patients (1%) was nil per os. Gastrostomy tube dependence at 6, 12, and 24 months was 53%, 25%, and 10%, respectively. The Diet/GT score was 5 (gastrostomy tube removed and soft/regular diet) for 47% at 6 months, 74% at 12 months, and 89% at 24 months. Multivariate analyses revealed that higher tumor stage was associated with a lower Diet/GT score at 12 months (P =. 02) and gastrostomy dependence at 12 months (P =. 01) and 24 months (P =. 04).Conclusion: Despite the addition of neck dissection to chemoradiotherapy, nearly all patients took a soft or regular diet and reached a Diet/GT score of 5, and only 1% remained nil per os. A higher tumor stage is associated with a lower Diet/GT score and gastrostomy tube dependency beyond 12 months.
- Open Access
- 15 November 2010
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 136 (11) , 1071-1077
Neck Dissection After Chemoradiotherapy
Neck management after chemoradiotherapy (CRT) for head and neck cancer has become a controversial topic. At most institutions, planned neck dissections (NDs) after CRT are often no longer routinely performed.1-3 Rather, the neck is assessed and, if findings suggest possible residual metastatic disease, ND is advised. Results of early neck dual-modality positron emission tomography/computed tomography (PET/CT) may be inaccurate owing to treatment-related inflammation, cancer in evolution toward death, and pockets of residual disease that are too small to detect on imaging.4,5 Several investigators have found improved accuracy when PET/CT is delayed until 3 months or more after treatment.1-3,6 However, this time frame has conflicted with the traditional thinking that posttreatment ND should be performed within 4 to 12 weeks after radiation to lessen the risk of surgical complications.7
- 15 November 2010
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 136 (11) , 1071-1077
Open AccessNeck Dissection After Chemoradiotherapy
Neck management after chemoradiotherapy (CRT) for head and neck cancer has become a controversial topic. At most institutions, planned neck dissections (NDs) after CRT are often no longer routinely performed.1-3 Rather, the neck is assessed and, if findings suggest possible residual metastatic disease, ND is advised. Results of early neck dual-modality positron emission tomography/computed tomography (PET/CT) may be inaccurate owing to treatment-related inflammation, cancer in evolution toward death, and pockets of residual disease that are too small to detect on imaging.4,5 Several investigators have found improved accuracy when PET/CT is delayed until 3 months or more after treatment.1-3,6 However, this time frame has conflicted with the traditional thinking that posttreatment ND should be performed within 4 to 12 weeks after radiation to lessen the risk of surgical complications.7
- 1 September 2010
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 143 (3) , 367-374
Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy
OBJECTIVE: To determine whether computed tomography can distinguish low risk neck levels that can be omitted when neck dissection is undertaken after chemoradiotherapy.STUDY DESIGN: Case series with chart review.SETTING: Tertiary care center.SUBJECTS AND METHODS: Head and neck squamous cell carcinoma patients undergoing neck dissection after chemoradiotherapy between January 1998 and June 2008. We compared computed tomography findings after chemoradiotherapy with neck dissection pathology results; used primary location and computed tomography findings to design selective or superselective neck dissection; and determined whether these surgeries would have contained all metastatic disease.RESULTS: A total of 104 patients were identified, providing 110 heminecks, 531 neck levels, and 3009 lymph nodes for analysis. Neck dissections were positive in 20 (19%) of 104 patients, corresponding to 20 hemineck dissections, 31 neck levels, and 53 lymph nodes. The negative predictive value for computed tomography was 95 percent. The negative predictive value for computed tomography per neck level was as follows: I, 100 percent; II, 96 percent; III, 96 percent; IV, 97 percent; and V, 96 percent. A selective neck dissection or a superselective neck dissection, guided by level specific computed tomography findings and limited to necks with post treatment partial response in one level, would have captured all disease in 52 (95%) of 55 and 51 (93%) of 55 heminecks.CONCLUSION: Negative computed tomography accurately predicts pathologic complete response at neck dissection. Neck dissection can be avoided in these patients. Additionally, computed tomography reliably identifies low risk neck levels that do not require dissection, permitting selective neck dissection or superselective neck dissection in partial response patients with limited residual disease.© 2010 American Academy of Otolaryngology‐Head and Neck Surgery Foundation. All rights reserved.
- 1 September 2010
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 143 (3) , 367-374
Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy
OBJECTIVE: To determine whether computed tomography can distinguish low risk neck levels that can be omitted when neck dissection is undertaken after chemoradiotherapy.STUDY DESIGN: Case series with chart review.SETTING: Tertiary care center.SUBJECTS AND METHODS: Head and neck squamous cell carcinoma patients undergoing neck dissection after chemoradiotherapy between January 1998 and June 2008. We compared computed tomography findings after chemoradiotherapy with neck dissection pathology results; used primary location and computed tomography findings to design selective or superselective neck dissection; and determined whether these surgeries would have contained all metastatic disease.RESULTS: A total of 104 patients were identified, providing 110 heminecks, 531 neck levels, and 3009 lymph nodes for analysis. Neck dissections were positive in 20 (19%) of 104 patients, corresponding to 20 hemineck dissections, 31 neck levels, and 53 lymph nodes. The negative predictive value for computed tomography was 95 percent. The negative predictive value for computed tomography per neck level was as follows: I, 100 percent; II, 96 percent; III, 96 percent; IV, 97 percent; and V, 96 percent. A selective neck dissection or a superselective neck dissection, guided by level specific computed tomography findings and limited to necks with post treatment partial response in one level, would have captured all disease in 52 (95%) of 55 and 51 (93%) of 55 heminecks.CONCLUSION: Negative computed tomography accurately predicts pathologic complete response at neck dissection. Neck dissection can be avoided in these patients. Additionally, computed tomography reliably identifies low risk neck levels that do not require dissection, permitting selective neck dissection or superselective neck dissection in partial response patients with limited residual disease.© 2010 American Academy of Otolaryngology‐Head and Neck Surgery Foundation. All rights reserved.
- 8 December 2009
- Published by Wiley in The Laryngoscope
- Vol. 120 (2) , 261-266
Combined antegrade and retrograde esophageal dilation for head and neck cancer‐related complete esophageal stenosis
Objectives/Hypothesis: Assess the safety and efficacy of combined antegrade and retrograde esophageal dilation (CARD) for complete esophageal stenosis following head and neck cancer (HNC) treatment. Review HNC dysphagia management.Study Design: Retrospective review of all patients undergoing CARD following HNC treatment between May 2001 and September 2008.Methods: Forty‐five patients were identified for review. Parameters assessed included: ability to obtain intraoperative esophageal patency, complications, number of dilations required, diet, and gastric tube (GT) status. Factors associated with dilation failure were analyzed.Results: Intraoperative esophageal patency was obtained in 91% of patients. Median number of all dilations per patient was three. Median number of CARDs per patient was one. Resumption of oral intake occurred in 36/45 (80%). Diet results included: regular or soft diet 32/45 (71%), GT removal 27/45 (60%), and GT dependence with nothing by mouth 9/45 (20%). Laryngeal and pharyngeal stenosis, radionecrosis, tracheotomy dependence, and elongated stenosis were associated with dilation failure. Complications occurred in 18/63 (29%) CARD procedures: eight pneumomediastinum, seven GT site problems, two esophageal perforations, and one pharyngeal infection. All complications resolved spontaneously or with minimal interventions.Conclusions: CARD was safe and effective. Intraoperative patency was achieved in 91% of patients. Eighty percent resumed oral intake. The majority of patients had their GTs removed and resumed a soft or regular diet. Dilation failure was associated with laryngeal, pharyngeal, and excessively long esophageal stenosis, often resulting from radionecrosis. Complications were minor. CARD should be considered before relegating patients with complete esophageal stenosis to chronic GT dependence or subjecting them to laryngopharyngo esophagectomy. Laryngoscope, 2010
- 8 December 2009
- Published by Wiley in The Laryngoscope
- Vol. 120 (2) , 261-266
Combined antegrade and retrograde esophageal dilation for head and neck cancer‐related complete esophageal stenosis
Objectives/Hypothesis: Assess the safety and efficacy of combined antegrade and retrograde esophageal dilation (CARD) for complete esophageal stenosis following head and neck cancer (HNC) treatment. Review HNC dysphagia management.Study Design: Retrospective review of all patients undergoing CARD following HNC treatment between May 2001 and September 2008.Methods: Forty‐five patients were identified for review. Parameters assessed included: ability to obtain intraoperative esophageal patency, complications, number of dilations required, diet, and gastric tube (GT) status. Factors associated with dilation failure were analyzed.Results: Intraoperative esophageal patency was obtained in 91% of patients. Median number of all dilations per patient was three. Median number of CARDs per patient was one. Resumption of oral intake occurred in 36/45 (80%). Diet results included: regular or soft diet 32/45 (71%), GT removal 27/45 (60%), and GT dependence with nothing by mouth 9/45 (20%). Laryngeal and pharyngeal stenosis, radionecrosis, tracheotomy dependence, and elongated stenosis were associated with dilation failure. Complications occurred in 18/63 (29%) CARD procedures: eight pneumomediastinum, seven GT site problems, two esophageal perforations, and one pharyngeal infection. All complications resolved spontaneously or with minimal interventions.Conclusions: CARD was safe and effective. Intraoperative patency was achieved in 91% of patients. Eighty percent resumed oral intake. The majority of patients had their GTs removed and resumed a soft or regular diet. Dilation failure was associated with laryngeal, pharyngeal, and excessively long esophageal stenosis, often resulting from radionecrosis. Complications were minor. CARD should be considered before relegating patients with complete esophageal stenosis to chronic GT dependence or subjecting them to laryngopharyngo esophagectomy. Laryngoscope, 2010
- 1 June 2006
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 134 (6) , 916-922
Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer
OBJECTIVES: Assess impact of sequential chemoradiation therapy (SCRT) for advanced head and neck cancer (HNCA) on swallowing, nutrition, and quality of life.STUDY DESIGN: Prospective cohort study of 59 patients undergoing SCRT for advanced head and neck cancer. Follow‐up median was 47.5 months.SETTING: Regional Cancer Center.RESULTS: Median time to gastrostomy tube removal was 21 weeks. Eighteen of 23 patients who underwent modified barium swallow demonstrated aspiration; none developed pneumonia. Six of 7 with pharyngoesophageal stricture underwent successful dilatation. Functional Assessment of Cancer Therapy—Head and Neck Scale questionnaires at median 6 months after treatment revealed “somewhat” satisfaction with swallowing. At the time of analysis, 97% have the gastronomy tube removed and take soft/regular diet.CONCLUSION: Early after treatment dysphagia adversely affected weight, modified barium swallow results, and quality of life. Diligent swallow therapy, and dilation as needed, allowed nearly all patients to have their gastronomy tubes removed and return to a soft/regular diet.SIGNIFICANCE: Dysphagia is significant after SCRT but generally slowly recovers 6 to 12 months after SCRT.
- 1 June 2006
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 134 (6) , 916-922
Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer
OBJECTIVES: Assess impact of sequential chemoradiation therapy (SCRT) for advanced head and neck cancer (HNCA) on swallowing, nutrition, and quality of life.STUDY DESIGN: Prospective cohort study of 59 patients undergoing SCRT for advanced head and neck cancer. Follow‐up median was 47.5 months.SETTING: Regional Cancer Center.RESULTS: Median time to gastrostomy tube removal was 21 weeks. Eighteen of 23 patients who underwent modified barium swallow demonstrated aspiration; none developed pneumonia. Six of 7 with pharyngoesophageal stricture underwent successful dilatation. Functional Assessment of Cancer Therapy—Head and Neck Scale questionnaires at median 6 months after treatment revealed “somewhat” satisfaction with swallowing. At the time of analysis, 97% have the gastronomy tube removed and take soft/regular diet.CONCLUSION: Early after treatment dysphagia adversely affected weight, modified barium swallow results, and quality of life. Diligent swallow therapy, and dilation as needed, allowed nearly all patients to have their gastronomy tubes removed and return to a soft/regular diet.SIGNIFICANCE: Dysphagia is significant after SCRT but generally slowly recovers 6 to 12 months after SCRT.
- 1 May 2006
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 132 (5) , 526-531
Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer
Objectives To (1) determine clinical factors that predict pathologic complete response (pCR) on neck dissection after sequential chemoradiotherapy (SCRT) for advanced head and neck cancer and (2) compare survival parameters between those who underwent neck dissection and those who did not among those patients with a clinical complete response (cCR) in the neck after SCRT, thus assessing the benefit of neck dissection in patients with a cCR in the neck. Design Retrospective review with a mean follow-up of 3.5 years. Setting Regional cancer center. Patients The study population comprised 55 patients undergoing SCRT for advanced head and neck cancer with N2 or N3 neck disease. Three patients developed progressive disease and were excluded, and 28 patients underwent neck dissection. Interventions Patients were assessed by physical examination and radiographically after SCRT. Main Outcome Measures Physical examination and radiographic assessments of residual neck disease were compared with pathologic findings in those patients who underwent neck dissection. Survival comparisons were made between patients with a cCR in the neck who underwent neck dissection and those who did not. Results Of 28 patients who underwent neck dissection, 8 had persistent pathologically positive nodal disease: 5 (45%) of 11 had N3 and 3 (18%) of 17 had N2 disease. Individual clinical neck assessments after SCRT were fairly predictive of a negative pathologic finding at neck dissection. The negative predictive values were physical examination (75%), computed tomography or magnetic resonance imaging (71%), and positron emission tomography (75%). However, when physical examination, imaging studies, and positron emission tomography all indicated a complete response, this accurately predicted a pCR on neck dissection. There appeared to be no improvement in survival parameters when a neck dissection was performed on patients with a cCR in the neck. Conclusions Patients with N3 disease are at high risk for residual neck metastasis after SCRT. Patients with N2 disease can be assessed with physical examination, imaging studies, and positron emission tomography. If these all indicate a cCR, then neck dissection is likely not needed. Neck dissection did not appear to further improve survival parameters for patients with a cCR in the neck.
- 1 May 2006
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 132 (5) , 526-531
Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer
Objectives To (1) determine clinical factors that predict pathologic complete response (pCR) on neck dissection after sequential chemoradiotherapy (SCRT) for advanced head and neck cancer and (2) compare survival parameters between those who underwent neck dissection and those who did not among those patients with a clinical complete response (cCR) in the neck after SCRT, thus assessing the benefit of neck dissection in patients with a cCR in the neck. Design Retrospective review with a mean follow-up of 3.5 years. Setting Regional cancer center. Patients The study population comprised 55 patients undergoing SCRT for advanced head and neck cancer with N2 or N3 neck disease. Three patients developed progressive disease and were excluded, and 28 patients underwent neck dissection. Interventions Patients were assessed by physical examination and radiographically after SCRT. Main Outcome Measures Physical examination and radiographic assessments of residual neck disease were compared with pathologic findings in those patients who underwent neck dissection. Survival comparisons were made between patients with a cCR in the neck who underwent neck dissection and those who did not. Results Of 28 patients who underwent neck dissection, 8 had persistent pathologically positive nodal disease: 5 (45%) of 11 had N3 and 3 (18%) of 17 had N2 disease. Individual clinical neck assessments after SCRT were fairly predictive of a negative pathologic finding at neck dissection. The negative predictive values were physical examination (75%), computed tomography or magnetic resonance imaging (71%), and positron emission tomography (75%). However, when physical examination, imaging studies, and positron emission tomography all indicated a complete response, this accurately predicted a pCR on neck dissection. There appeared to be no improvement in survival parameters when a neck dissection was performed on patients with a cCR in the neck. Conclusions Patients with N3 disease are at high risk for residual neck metastasis after SCRT. Patients with N2 disease can be assessed with physical examination, imaging studies, and positron emission tomography. If these all indicate a cCR, then neck dissection is likely not needed. Neck dissection did not appear to further improve survival parameters for patients with a cCR in the neck.
- 1 November 2004
- Published by Wiley in The Laryngoscope
- Vol. 114 (11) , 1924-1931
Endoscopic Management of Hypopharyngeal Stenosis after Organ Sparing Therapy for Head and Neck Cancer
- 1 November 2004
- Published by Wiley in The Laryngoscope
- Vol. 114 (11) , 1924-1931
Endoscopic Management of Hypopharyngeal Stenosis after Organ Sparing Therapy for Head and Neck Cancer